Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
about
The Blood Pressure "Uncertainty Range" - a pragmatic approach to overcome current diagnostic uncertainties (II)Optimizing blood pressure control in patients with chronic kidney disease.Evidence-based approach for managing hypertension in type 2 diabetes.A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goalsBlood pressure control and nephroprotection in diabetes.Initial monotherapy and combination therapy and hypertension control the first yearThe importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy.Management strategies for patients with hypertension and diabetes: why combination therapy is critical.Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker.The relationships of sleep apnea, hypertension, and resistant hypertension on chronic kidney disease.Risk-based classification of hypertension and the role of combination therapy.Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker.Prompt, aggressive BP lowering in high-risk patients.State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.A role for single-pill triple therapy in hypertension.Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) studyHypertension and chronic kidney disease progression: why the suboptimal outcomes?Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus.How early should blood pressure control be achieved for optimal cardiovascular outcomes?Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension.The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.
P2860
Q24793325-DE84F565-394A-4643-926C-1F04E4535997Q33979430-4ACCF606-3F32-43CA-A51D-FD8713D95382Q35210531-16CD12A3-EFC1-45B6-ADF8-F7B1C2F83464Q35210558-54715062-9EDC-4499-B27C-EF2A9E7C5D41Q35722933-48BA915D-3B46-477B-BCA8-27A8546C7AC9Q36184174-E8333876-DD86-466E-8ED3-97AC3B925791Q36362376-56BF37EA-5A2F-4240-AD08-BD8C98228C4FQ36392677-9A8F9B80-13A5-473A-8C19-66D5BC10A983Q36863534-D4524914-872C-4C1A-A107-0E056891515BQ36961390-A354F963-6CDE-4F74-AF47-B7006A7E4B8FQ37003711-BBF87ECB-B7B9-4D77-9B8E-5D042FABA938Q37050143-A83508FF-F941-4D33-B48B-D38A47A373D6Q37050156-2AC8651F-BE4D-4B4D-BDE7-41007840927DQ37050163-C1634B89-5125-4437-8BC3-E888708ED398Q37078824-6FB34752-64BD-4A7B-B973-147CB061F2D6Q37078827-5332F5DB-7394-4DE4-8E5B-90E35F0E47FEQ37202153-99B0502D-51B4-4259-A1D1-4BD1209E0DCAQ37483049-B3CAFB08-073C-4584-9C75-A35590A815ECQ37569342-4007DE53-8698-4FD0-9F1C-B33A8EC073F8Q37618602-27118E86-D2F4-483E-A2B7-8881A111EBD3Q37629831-67739BFF-0ABE-45D4-8B5C-4B5055270925Q37769409-8F8E0CB2-75EA-4E92-BCAA-6AD7A05796CEQ43248376-C3C40F78-7DE7-4A32-B4BD-48852BDCA010Q45016829-7E8EC060-D6FA-4848-B9DF-CFF9EDE0EEA0Q45085165-47CBA3C9-6C70-4622-81FF-33965D6EB816Q46303348-E751FD28-004A-40BE-840D-B97A28D6385FQ47124918-DE63D490-E075-4984-B710-39B9669C0153Q51560465-D7B18E7B-90FC-44BF-ADE4-23E35E9BFDBA
P2860
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Achieving goal blood pressure ...... d-dose combination approaches.
@en
Achieving goal blood pressure ...... d-dose combination approaches.
@nl
type
label
Achieving goal blood pressure ...... d-dose combination approaches.
@en
Achieving goal blood pressure ...... d-dose combination approaches.
@nl
prefLabel
Achieving goal blood pressure ...... d-dose combination approaches.
@en
Achieving goal blood pressure ...... d-dose combination approaches.
@nl
P2093
P2860
P1476
Achieving goal blood pressure ...... d-dose combination approaches.
@en
P2093
George L Bakris
Matthew R Weir
Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators
P2860
P304
P356
10.1111/J.1524-6175.2002.2041.X
P577
2003-05-01T00:00:00Z